1. Home
  2. AGMH vs ARTL Comparison

AGMH vs ARTL Comparison

Compare AGMH & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AGM Group Holdings Inc.

AGMH

AGM Group Holdings Inc.

HOLD

Current Price

$1.27

Market Cap

4.2M

Sector

Technology

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.17

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGMH
ARTL
Founded
2015
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
3.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
AGMH
ARTL
Price
$1.27
$1.17
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$30.00
AVG Volume (30 Days)
33.7K
27.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.85
52 Week High
$18.10
$28.60

Technical Indicators

Market Signals
Indicator
AGMH
ARTL
Relative Strength Index (RSI) 31.08 42.77
Support Level $0.06 $1.10
Resistance Level $2.46 $1.50
Average True Range (ATR) 0.09 0.13
MACD 0.01 0.00
Stochastic Oscillator 7.69 33.33

Price Performance

Historical Comparison
AGMH
ARTL

About AGMH AGM Group Holdings Inc.

AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: